faldaprevir

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
05101520132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND & AIMS The safety and efficacy of the interferon-free combination of faldaprevir (NS3/A4 protease inhibitor… (More)
Is this relevant?
2014
2014
Faldaprevir, an investigational agent for hepatitis C virus treatment, is well tolerated but associated with rapidly reversible… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of… (More)
Is this relevant?
2014
2014
An increased appreciation of the importance of transporter and enzyme interplay in drug clearance and a desire to delineate these… (More)
Is this relevant?
2014
2014
Hepatocytes provide an integrated model to study drug metabolism and disposition. As a result of a loss of polarity or a… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Chronic hepatitis C virus (HCV) infection is characterised by a failure of virus-specific CD8+ T cells that is… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
UNLABELLED Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2013
2013
UNLABELLED Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor. In all, 290 noncirrhotic HCV… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
BACKGROUND Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the… (More)
  • figure 1
  • table 1
Is this relevant?